Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline Review, H1 2017’, provides an overview of the Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)

The report reviews pipeline therapeutics for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) therapeutics and enlists all their major and minor projects

The report assesses Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

bluebird bio Inc

MedDay SA

Minoryx Therapeutics sl

Pfizer Inc

ReceptoPharm Inc

Viking Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Overview

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Companies Involved in Therapeutics Development

bluebird bio Inc

MedDay SA

Minoryx Therapeutics sl

Pfizer Inc

ReceptoPharm Inc

Viking Therapeutics Inc

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Drug Profiles

biotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DRX-065 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DUOC-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate ABCD1 for Adrenoleukodystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lenti-D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGTA-456 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIN-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pioglitazone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPI-78M - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

temsirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VK-0214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VK-2809 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Dormant Projects

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Product Development Milestones

Featured News & Press Releases

Mar 21, 2017: Minoryx Therapeutics successfully completes phase 1 clinical trial for lead candidate MIN-102

Feb 22, 2017: Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102

Jan 18, 2017: Minoryx Therapeutics further strengthens its Scientific Advisory Board (SAB)

Dec 14, 2016: Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102

Dec 06, 2016: Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy

Sep 26, 2016: Viking Therapeutics Presents Positive Proof-of-Concept Data for VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy at the 86th Annual Meeting of the American Thyroid Association

Sep 14, 2016: Positive Preclinical Data With MD1003 (High Dose Pharmaceutical Grade Biotin) in X-Linked Adrenoleukodystrophy to be Presented at European Committee for Treatment and Research in Multiple Sclerosis 2016

Jul 26, 2016: Viking Therapeutics Announces Positive Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)

Jul 06, 2016: Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

Jun 14, 2016: Minoryx Therapeutics appoints Dr. Uwe Meya as Chief Medical Officer

Apr 03, 2014: Minoryx receives Orphan Drug Designation for MIN-101

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Applied Genetic Technologies Corp, H1 2017

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by bluebird bio Inc, H1 2017

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by MedDay SA, H1 2017

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Minoryx Therapeutics sl, H1 2017

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Pfizer Inc, H1 2017

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by ReceptoPharm Inc, H1 2017

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Viking Therapeutics Inc, H1 2017

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports